Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
暂无分享,去创建一个
G. Sawicki | S. McColley | C. Owen | D. Waltz | G. Marigowda | Chonghua Li | J. McNamara | S. Tian | Linda T. Wang | Fang Liu | David Stiles